Cardiovascular disease and chronic kidney disease: Insights and an update

Patricia Best, Donal N. Reddan, Peter B. Berger, Lynda A. Szczech, Peter A. McCullough, Robert M. Califf

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Despite the high prevalence and significant morbidity and mortality rates of chronic kidney disease (CKD) related to cardiovascular disease, it remains vastly understudied. Most of the current practice recommendations come from small under-powered prospective studies, retrospective reviews, and assuming patients with CKD will similarly benefit from medications and treatments as patients with normal renal function. In addition, because of the previous lack of a consistent definition of CKD and how to measure renal function, definitions of the degree of renal dysfunction have varied widely and compounded the confusion of these data. Remarkably, despite patients with CKD representing the group at highest risk from cardiovascular complications, even greater than patients with diabetes mellitus, there has been a systematic exclusion of patients with CKD from therapeutic trials. This review outlines our current understanding of CKD as a cardiovascular risk factor, treatment options, and the future directions that are needed to treat cardiovascular disease in patients with CKD.

Original languageEnglish (US)
Pages (from-to)230-242
Number of pages13
JournalAmerican Heart Journal
Volume148
Issue number2
DOIs
StatePublished - Aug 1 2004

Fingerprint

Chronic Renal Insufficiency
Cardiovascular Diseases
Kidney
Diabetes Mellitus
Therapeutics
Prospective Studies
Morbidity
Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Best, P., Reddan, D. N., Berger, P. B., Szczech, L. A., McCullough, P. A., & Califf, R. M. (2004). Cardiovascular disease and chronic kidney disease: Insights and an update. American Heart Journal, 148(2), 230-242. https://doi.org/10.1016/j.ahj.2004.04.011

Cardiovascular disease and chronic kidney disease : Insights and an update. / Best, Patricia; Reddan, Donal N.; Berger, Peter B.; Szczech, Lynda A.; McCullough, Peter A.; Califf, Robert M.

In: American Heart Journal, Vol. 148, No. 2, 01.08.2004, p. 230-242.

Research output: Contribution to journalArticle

Best, P, Reddan, DN, Berger, PB, Szczech, LA, McCullough, PA & Califf, RM 2004, 'Cardiovascular disease and chronic kidney disease: Insights and an update', American Heart Journal, vol. 148, no. 2, pp. 230-242. https://doi.org/10.1016/j.ahj.2004.04.011
Best, Patricia ; Reddan, Donal N. ; Berger, Peter B. ; Szczech, Lynda A. ; McCullough, Peter A. ; Califf, Robert M. / Cardiovascular disease and chronic kidney disease : Insights and an update. In: American Heart Journal. 2004 ; Vol. 148, No. 2. pp. 230-242.
@article{b14e60305ced4b00a197acd0ac81fb3b,
title = "Cardiovascular disease and chronic kidney disease: Insights and an update",
abstract = "Despite the high prevalence and significant morbidity and mortality rates of chronic kidney disease (CKD) related to cardiovascular disease, it remains vastly understudied. Most of the current practice recommendations come from small under-powered prospective studies, retrospective reviews, and assuming patients with CKD will similarly benefit from medications and treatments as patients with normal renal function. In addition, because of the previous lack of a consistent definition of CKD and how to measure renal function, definitions of the degree of renal dysfunction have varied widely and compounded the confusion of these data. Remarkably, despite patients with CKD representing the group at highest risk from cardiovascular complications, even greater than patients with diabetes mellitus, there has been a systematic exclusion of patients with CKD from therapeutic trials. This review outlines our current understanding of CKD as a cardiovascular risk factor, treatment options, and the future directions that are needed to treat cardiovascular disease in patients with CKD.",
author = "Patricia Best and Reddan, {Donal N.} and Berger, {Peter B.} and Szczech, {Lynda A.} and McCullough, {Peter A.} and Califf, {Robert M.}",
year = "2004",
month = "8",
day = "1",
doi = "10.1016/j.ahj.2004.04.011",
language = "English (US)",
volume = "148",
pages = "230--242",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Cardiovascular disease and chronic kidney disease

T2 - Insights and an update

AU - Best, Patricia

AU - Reddan, Donal N.

AU - Berger, Peter B.

AU - Szczech, Lynda A.

AU - McCullough, Peter A.

AU - Califf, Robert M.

PY - 2004/8/1

Y1 - 2004/8/1

N2 - Despite the high prevalence and significant morbidity and mortality rates of chronic kidney disease (CKD) related to cardiovascular disease, it remains vastly understudied. Most of the current practice recommendations come from small under-powered prospective studies, retrospective reviews, and assuming patients with CKD will similarly benefit from medications and treatments as patients with normal renal function. In addition, because of the previous lack of a consistent definition of CKD and how to measure renal function, definitions of the degree of renal dysfunction have varied widely and compounded the confusion of these data. Remarkably, despite patients with CKD representing the group at highest risk from cardiovascular complications, even greater than patients with diabetes mellitus, there has been a systematic exclusion of patients with CKD from therapeutic trials. This review outlines our current understanding of CKD as a cardiovascular risk factor, treatment options, and the future directions that are needed to treat cardiovascular disease in patients with CKD.

AB - Despite the high prevalence and significant morbidity and mortality rates of chronic kidney disease (CKD) related to cardiovascular disease, it remains vastly understudied. Most of the current practice recommendations come from small under-powered prospective studies, retrospective reviews, and assuming patients with CKD will similarly benefit from medications and treatments as patients with normal renal function. In addition, because of the previous lack of a consistent definition of CKD and how to measure renal function, definitions of the degree of renal dysfunction have varied widely and compounded the confusion of these data. Remarkably, despite patients with CKD representing the group at highest risk from cardiovascular complications, even greater than patients with diabetes mellitus, there has been a systematic exclusion of patients with CKD from therapeutic trials. This review outlines our current understanding of CKD as a cardiovascular risk factor, treatment options, and the future directions that are needed to treat cardiovascular disease in patients with CKD.

UR - http://www.scopus.com/inward/record.url?scp=4143068072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4143068072&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2004.04.011

DO - 10.1016/j.ahj.2004.04.011

M3 - Article

C2 - 15308992

AN - SCOPUS:4143068072

VL - 148

SP - 230

EP - 242

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 2

ER -